New capability delivers seamless interoperability and global connectivity, laying the foundation for end-to-end regulatory integration March 24, 2026 01:00 ET  | Source: Accumulus Technologies SAN FRANCISCO, March 24, 2026 (GLOBE NEWSWIRE) — Accumulus Technologies today announced the launch of the Accumulus Connector (“Connector”), a new platform capability that extends the Accumulus platform into customers’ existing technology stacks, […]

March 23, 2026 11:46 ET  | Source: ProductLife Group (PLG) PARIS, March 23, 2026 (GLOBE NEWSWIRE) — ProductLife Group (PLG), a global provider of consulting and outsourcing services for the life sciences industry, has appointed Dr. James Burt as Chief Executive Officer. Dr. Burt brings more than 20 years of international leadership experience across the pharmaceutical value

Updated European Association of Urology guidelines reflect growing clinical evidence supporting Aquablation therapy in the surgical treatment of benign prostatic hyperplasia March 23, 2026 07:00 ET  | Source: PROCEPT BioRobotics SAN JOSE, Calif., March 23, 2026 (GLOBE NEWSWIRE) — PROCEPT BioRobotics® (Nasdaq: PRCT) today highlighted the latest update to the European Association of Urology (EAU) Guidelines for male

March 23, 2026 05:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: The agenda furthermore includes a proposal

March 23, 2026 04:30 ET  | Source: Royal Philips March 23, 2026 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a proposed Supervisory Board appointment and re-appointments, in addition to the previously announced proposal to re-appointment its President/CEO. The Supervisory Board will submit to the Annual General Meeting of Shareholders

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its website. Q1 2026 Aide Memoire Teva has compiled this document with public information that was

March 19, 2026 16:30 ET  | Source: Teva Pharmaceutical Industries Ltd TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2026 financial results on Wednesday, April 29, 2026, at 7:00 a.m. ET. Following

March 19, 2026 09:00 ET  | Source: Curia Global, Inc. ALBANY, N.Y., March 19, 2026 (GLOBE NEWSWIRE) — Curia, a leading contract research, development and manufacturing organization (CDMO), today announced progress on the expansion at its Glasgow, UK sterile drug product facility as well as enhancements to its proprietary platform for cell line development. The Glasgow, UK,

March 19, 2026 07:00 ET  | Source: Tilray Brands, Inc. NEW YORK and SYDNEY, March 19, 2026 (GLOBE NEWSWIRE) — Tilray Medical, a recognized global leader in medical cannabis and a division of Tilray Brands, Inc. (“Tilray”) (Nasdaq: TLRY; TSX: TLRY), today announced its largest portfolio expansion in Australia to date. The expanded medical cannabis offering reinforces

March 19, 2026 04:00 ET  | Source: SK pharmteco Inc. RANCHO CORDOVA, Calif., March 19, 2026 (GLOBE NEWSWIRE) — SK pharmteco today announced a significant funding commitment to support strategic initiatives within its viral vector business, while reaffirming its long-term growth strategy across three business units: small molecule, peptides, and viral vectors. SK pharmteco is sharpening its

AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancer March 18, 2026 08:36 ET  | Source: AIM ImmunoTech Inc. OCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) — AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s

Four presentations deliver new insights into zanidatamab, including its differentiated HER2 biology March 18, 2026 07:46 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia, March 18, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that the

March 18, 2026 05:00 ET  | Source: Boehringer Ingelheim Limited World Parasite Awareness Day, held annually on March 20, is an important reminder that parasites such as fleas, ticks and worms are among the most common health threats for pets around the world, yet they can easily be prevented.     A global survey among 6,500 pet owners1 shows

March 17, 2026 17:02 ET  | Source: Zymeworks Inc. VANCOUVER, British Columbia , March 17, 2026 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced the acceptance of an oral presentation and six abstracts from its wholly-owned R&D

March 17, 2026 16:35 ET  | Source: Adagene Inc. SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) — Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced that muzastotug will be highlighted in two poster presentations at this year’s AACR Meeting, taking place